Sign in
Not yet recruitingPhase 3

Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

Key facts

Who runs it
Virchow Group
Where
India2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
44 people, planned
Started
1 Jul 2025
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • IVIG-VImmune
  • IVIG-Immuglo
Record updated
12 June 2025

Who can take part

Age
2 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Male or female, aged 2 to 65 years
  • Patients with confirmed diagnosis of primary immunodeficiency, predominantly antibody deficient, or common variable immunodeficiency (CVID) with a history of hypogammaglobulinemia (i.e., IgG<500 mg/dl) or X-linked agammaglobulinemia (XLA)
  • Treatment naive patients eligible to receive intravenous immunoglobulin or, patients already on intravenous immunoglobulin infusions every 3 or every 4 weeks for ≥6 months at a dose aimed to be between 200 and 800 mg/kg with at least two documented IgG trough levels in the previous two infusions before enrolment in the study
  • The screening laboratory tests must meet the following criteria:; WBC ≥3.5 x 109/L; Neutrophils ≥1.5 x 109/L; Platelets ≥100 x 109/L; Serum transaminase ≤2 times the upper limit of normal; Alkaline phosphatase levels ≤2 times the upper limit of normal; Serum creatinine ≤150 µmol/L (≤1.7mg/dl)
  • Patients must be able to adhere to the study visit schedule and other protocol requirements
  • If subject is a female and is; -of child bearing potential, she should be practicing an acceptable method of birth control for the duration of tl1e study as suggested by the investigator, such as a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier method), intrauterine device (IUD), or abstinence OR surgically sterile, bilateral tubal ligation done at least 6 months before the study should be documented
  • Patients/LAR must be capable of giving informed consent, and written consent must have been obtained prior to any study procedures

Who cannot take part

  • History or presence of any form of cancer prior to enrollment
  • Patients with selective IgA deficiency or antibodies IgA
  • Requirement for use of glucocorticosteroids above 0.15 mg of prednisone equivalent/kg/day and other immunosupressive drugs as concomitant medication
  • Participation in any clinical study within the previous 3 months
  • Patients with secondary immunodeficiency diseases
  • History of any autoimmune disease
  • History of adverse or allergic reactions to other IgG or blood products
  • History of acute renal failure or severe renal impairment, or deep venous thrombosis which in the opinion of the Investigator, may place the patient at unacceptable risk for study participation and may prevent the patient from completing the study
  • History of congestive heart failure [New York Heart Association class III/IV] or unstable angina
  • Recent history of migraine, hyperprolinemia, and lymphoid malignancy
  • History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the patient at unacceptable risk for study participation and may prevent the patient from completing the study
  • Pregnant women, nursing mothers or a planned pregnancy within 18 months of participation
  • Patients requires any blood transfusion during the study
  • Patients with T-cell related Severe combined immunodeficiency
  • Positive at screening for any markers of infectious blood borne viruses
  • Patient, who in the opinion of the Investigator, is not suitable for participation in the clinical study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Primary immunodeficiency diseases

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments

The 2 groups in the trial

  • Test ArmTreatment being tested

    200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose.

    Treatment: IVIG-VImmune

  • ReferenceExisting treatment, for comparison

    Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose

    Treatment: IVIG-Immuglo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open- Label, Multicentre, Phase III Clinical Comparative Study to Evaluate the Efficacy, Safety and Pharmacokinetic Properties of Human Normal Immunoglobulin in Patients With Primary Immunodeficiency Disease
Criteria questions
Built from NCT07017036, who can take part
Record updated
12 June 2025